Comparison in Efficacy and Safety Between Interferon Alfacon-1 Alone and Concomitant Dosing With Ribavirin for the Treatment of Hepatitis C
Phase 3
Completed
- Conditions
- Hepatitis C
- Registration Number
- NCT00239252
- Lead Sponsor
- Astellas Pharma Inc
- Brief Summary
Efficacy and safety is compared between interferon alfacon-1 alone and concomitant dosing of interferon alfacon-1 and ribavirin in hepatitis C patients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- Hepatitis C patients (high titer, genotype1)
Exclusion Criteria
- Patients with autoimmune disorder
- Patients with negative HBs antigen
- Patients with hepatic cirrhosis, hepatic failure and hepatic cancer
- Patients with depression or psychoneurotic disorder
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method